Cognition Therapeutics, Inc. is a clinical stage pharmaceutical company targeting neurodegenerative disorders. Our lead molecule CT1812 is currently in the clinic for Alzheimer’s disease. Located in Pittsburgh’s historic South Side, we are seeking highly motivated individuals to work in a dynamic industry environment.
The candidate will be a key contributor in a scientific research team using big data approaches to define drug candidate cellular and molecular mechanism of action space. Responsibilities include supervising collaborator and leading internal efforts to analyze large protein data sets, available bioinformatics databases and scientific literature to extract data relevant to target proteins, constructing signaling pathways relevant to compound mechanism of action, and modeling compound impact on target proteins in disease states. The candidate will work with others in a team-based environment and make formal presentations of results to the company.
B.A., B.S., M.S., or Ph.D. in bioinformatics
Expertise in coding (R/Python), available bioinformatics database searching, pathway mapping software
Experience in pharmacokinetic/pharmacodynamic modeling and neurodegenerative disease biology
Industry experience a plus
Internal Number: 001
About Cognition Therapeutics
Cognition Therapeutics, Inc. (CogRx) is a
privately held biopharmaceutical company whose disease-relevant screening and novel
chemistry platforms have produced a pipeline of disease modifying small molecule drug
candidates which are being developed to treat Alzheimer’s disease and potentially other
neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class,
orally available small molecule that is currently in clinical trials in patients with
mild-to-moderate Alzheimer’s disease. This highly brain penetrant compound targets
the sigma-2 receptor complex, displacing toxic beta amyloid oligomers from their
binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has
been shown in multiple Alzheimer’s disease models to stop memory loss. Additional
information about Cognition may be found online at http://www.cogrx.com.